Holen Sie sich die Stockscreener-App
78.25
2.60%
-2.0679
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - simplywall.st
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
Dianthus Therapeutics closes $719M public offering - Investing.com
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus Therapeutics Announces Major Public Equity Offering - TipRanks
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York
Best Biotech Stocks To ConsiderMarch 11th - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics says co. prices upsized offering of 7,313,582 shares at $81.00 per share - marketscreener.com
Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewswire Inc.
Dianthus Therapeutics’ CAPTIVATE Trial Sparks Renewed Investor Interest - timothysykes.com
Surge in Dianthus Therapeutics Stock Amid Positive Trial Results - StocksToTrade
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally - AlphaStreet
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Raised to Strong-Buy at Raymond James Financial - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Finviz
Investment firm Raymond James announced an upgrade of biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) stock rating from "Outperform" to "Strong Buy". - Bitget
Beyond the Balance Sheet: What SWOT Reveals About Dianthus Thera - GuruFocus
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Dianthus Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks - TipRanks
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Cowen Maintains Buy on DNTH and Oppenheimer Keeps Outperform March 2026 - Meyka
Clear Street raises Dianthus Therapeutics price target on CIDP trial data - Investing.com Canada
Guggenheim’s Bold Move: Price Target for Dianthus Doubles to $200 - timothysykes.com
Dianthus Therapeutics announces proposed $400 million underwritten public offering - marketscreener.com
Dianthus Therapeutics Announces Proposed $400 Million Underwritten Public Offering - TradingView
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares fall 5% after announcing $400 million stock offering - Investing.com Canada
Jefferies raises Dianthus Therapeutics stock price target on CIDP trial progress - Investing.com Canada
Dianthus Therapeutics launches $400M stock offering By Investing.com - Investing.com Canada
Dianthus Therapeutics stock rallies—rare disease study success fuels optimism - MSN
Dianthus plans $400M share sale to fund autoimmune drug trials - Stock Titan
Biotech Stocks To Add to Your WatchlistMarch 9th - MarketBeat
Dianthus Therapeutics Reports 2025 Financial Results and Advancements in Claseprubart Phase 3 Trials for Autoimmune Diseases - Minichart
Guggenheim Boosts Price Target for Dianthus as Sales Projections Soar - StocksToTrade
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Asianet Newsable
HC Wainwright Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $130.00 - MarketBeat
Guggenheim Doubles Price Target for Dianthus: A Promising Future? - timothysykes.com
Dianthus Therapeutics stock maintained at Buy by TD Cowen - Investing.com Canada
Oppenheimer raises Dianthus Therapeutics price target on CIDP data By Investing.com - Investing.com Canada
Guggenheim Doubles Dianthus Price Target Amid Claseprubart Success - StocksToTrade
Stifel raises Dianthus Therapeutics price target on CIDP trial data By Investing.com - Investing.com Canada
Dianthus Therapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, Risk Factors, and Financials (Form 10-K) - Minichart
Dianthus Stock Surges on Guggenheim and Wedbush Price Target Boost - timothysykes.com
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Misses Estimates By $0.46 EPS - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst Upgrade - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Dianthus Therapeutics stock surges on early CIDP trial success - Investing.com India
Dianthus Therapeutics stock surges on early CIDP trial success By Investing.com - Investing.com Canada
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):